Skip to content
Screener

Ionis Pharmaceuticals IONS Ionis Operations — Research And Development Support Expenses

Similar metrics at other companies

Eve Holding logo
EVEXService Support — Research And Development Expense
$2.55M+91.1%
Zymeworks logo
ZYMEDevelopment support payments — Research and development collaborations
$291K-38.7%
Beam Therapeutics logo
BEAMExternal Research And Development Expenses — Research And Development Expense
$30.08M-12.6%
Helios Technologies logo
HLIOUnallocated Expenses — Research And Development Expense
$0
Solid Biosciences Inc. logo
SLDBInternal Research And Development Expense — Research And Development Expense
$9.06M+33.9%
Mineralys Therapeutics, Inc. logo
MLYSResearch and development expenses
$4.59M-52.5%

Other financials

Income statement

See full
Revenue$267.9M-40.7%
Gross profit$265.2M-40.8%
Operating income-$102.3M-173%
Net income-$114.6M-193%
EPS (diluted)-$0.69-199%

Balance sheet

See full
Cash & equivalents$350.1M+17.7%
Total debt$262.5M-67.0%
Total equity$439.7M-30.4%
Total assets$3.0B+0.3%

Cash flow

See full
Operating cash flow-$792.8M-426%
CapEx$16.1M+30.7%
Free cash flow-$814.6M-399%

Valuation

See full
Market cap$9.01B+38.9%
Enterprise value$8.92B+27.7%
P/S10.3×+3.4×

Profitability

See full
Gross margin98.2%-0.7pp
Operating margin-68%-234pp
Net margin-64.7%-299pp
FCF margin-77.4%+35.3pp

Returns & leverage

See full
Return on equity-105.5%+336pp
Debt / equity0.6×-0.7×
Current ratio7.9×+5.0×

Where this comes from

Reported directly by Ionis Pharmaceuticals in its filing.

Tagged under the XBRL concept ions:ResearchAndDevelopmentSupportExpenses.

The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.

Filed
Jul 29, 2026, 5:05 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0000874015-26-000251
Line itemThree Months Ended / June 30, 2026Three Months Ended / June 30, 2025Six Months Ended / June 30, 2026Six Months Ended / June 30, 2025
Drug discovery29,12030,25557,67757,244
Drug development103,958117,689208,140230,635
Medical affairs11,3187,82621,30713,468
Manufacturing and development chemistry20,63921,54540,94735,826
R&D support26,97420,60749,40541,159
Selling, general and administrative130,07581,081262,012148,061
Other segment items (1)57,94845,95476,33075,750
Consolidated net income (loss)$$(114,646)$123,551$(207,174)(23,387)

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Ionis Pharmaceuticals's ionis operations — research and development support expenses?
Ionis Pharmaceuticals (IONS) reported ionis operations — research and development support expenses of $26.97M in Q2 2026.
How has Ionis Pharmaceuticals's ionis operations — research and development support expenses changed year-over-year?
Ionis Pharmaceuticals's ionis operations — research and development support expenses increased by 30.9% year-over-year, from $20.61M to $26.97M.
What is the long-term trend for Ionis Pharmaceuticals's ionis operations — research and development support expenses?
Over 3 years (2022 to 2025), Ionis Pharmaceuticals's ionis operations — research and development support expenses has grown at a 16.6% compound annual growth rate (CAGR), from $59.84M to $94.85M.
What does ionis operations — research and development support expenses mean?
These are the indirect costs and overheads associated with supporting the R&D organization, including facility costs, administrative support, and infrastructure for research operations. It represents the foundational investment required to maintain a functional R&D environment.

Ask your AI about Ionis Pharmaceuticals's ionis operations — research and development support expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude